Danish Covid-19 therapy shows promise in phase I trial
Union Therapeutics' study with the drug niclosamide for treating Covid-19 patients with kidney diseases shows promising data in a Danish phase I trial program.
ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Biotech company Union Therapeutics is excited about positive preliminary trial data involving the company's niclosamide nasal spray, which it hopes will have an efficient impact on kidney patients with Covid-19.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
